BioPharmSignal logoBioPharmSignal

Biotech News

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Innoviva (INVA)InnovivaEarnings

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth IST product portfolio

Related news

INVAInnoviva2026-08-05 20:05 EST

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

INVAInnoviva2026-05-06 20:05 EST

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

FULCFulcrum Therapeutics2026-02-24 12:01 EST

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

FULCFulcrum Therapeutics2026-04-27 11:00 EST

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

PMVPPMV Pharmaceuticals2026-05-12 12:00 EST

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2025-11-12 13:01 EST

PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

ZNTLZentalis2025-11-10 21:05 EST

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

EXELExelixis2026-02-10 21:05 EST

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

EXELExelixis2026-01-27 21:05 EST

Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026

View all latest news

Innoviva

Diversified Biopharmaceutical Model Innoviva combines a respiratory-royalty portfolio, a commercial critical-care and infectious-disease business, and strategic investments in healthcare companies. Respiratory Royalties The company receives royalties from respiratory medicines partnered with GSK, providing cash flows that support...

Recent company news

INVAInnoviva2026-08-05 20:05 EST

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

INVAInnoviva2026-06-18 12:00 EST

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

INVAInnoviva2026-06-16 12:00 EST

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

INVAInnoviva2026-06-01 15:00 EST

Innoviva to Participate in Upcoming Investor Conferences

INVAInnoviva2026-05-06 20:05 EST

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Stock data

Close
21.11 USD
Market cap
1.58B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States